Generic Peptides Tesamorelin 2, 5 and 10 mg Research Vials

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone. Its chain is made of all 44 amino acids of human GHRH with a trans-3-hexenoic acid group added at one end, which protects it from being cut by the enzyme dipeptidyl aminopeptidase. Its formula is C221H366N72O67S and its mass is around 5136 g/mol. Under the brand names Egrifta, Egrifta SV and Egrifta WR it is a prescription product for a specific lipodystrophy indication.

It binds the growth hormone-releasing hormone receptor and drives the pituitary to make and release its own growth hormone, which also lifts IGF-1 levels. The terminal modification makes the molecule more potent and slower to break down than natural GHRH. In the clinical literature the fat reducing effect is described as lipolysis first, followed by a drop in triglycerides, rather than as a general weight loss effect.

The approved label lists the most common reactions, above five percent, as arthralgia, redness and itching at the injection site, pain in the limbs, peripheral oedema and muscle pain. It also warns about raised IGF-1, fluid retention, glucose intolerance or diabetes, and an increased risk of tumours, and it is contraindicated in pregnancy and in people with a disrupted hypothalamic-pituitary axis. This research vial is not that product.

Add sterile or bacteriostatic water down the side of the vial and swirl, do not shake, then divide the milligrams on the vial by the millilitres added to read mg per mL. Keep the sealed powder at 2-8 C or -20 C and let it reach room temperature before opening. The mixed solution stays at 2-8 C and is used within about four weeks.

Yes. The WADA Prohibited List 2026 names tesamorelin in class S2.2.4, growth hormone releasing factors, in the GHRH and analogues group. Category S2 substances are prohibited at all times, in and out of competition. The same line also names sermorelin and CJC-1295, and the wording is written as a catch-all, so related GHRH analogues are covered even when they are not printed.

Both act on the same receptor, but they are different lengths of the same hormone. Sermorelin is only the 1-29 fragment of human GHRH and gives a short pulse, while tesamorelin carries all 44 amino acids plus a fatty acid cap, so it resists enzymatic cleavage and holds the signal longer. That difference in stability, rather than a difference in receptor, is what separates the two products in practice.

All three vial sizes are listed on this page as research material with international and U.S. domestic checkout. International shipping runs about 35 dollars with a transit window of four to ten days, the domestic option is available on the 10 mg vial, and orders are handled within one to two business days. Stock and prices are shown live on the page.